1. Changes in weight and waist size in the rimonabant- and placebo-treated groups
End point
Rimonabant 20 mg (n=339)
Placebo (n=348) p
Weight (kg)
-5.3
-1.4
<0.001
Waist circumference (cm)
-5.2
-1.9
Scheen A. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.

2. HDL cholesterol and triglyceride parameters in the rimonabant- and placebo-treated groups
End point
Rimonabant 20 mg (n=339)
Placebo (n=348)
Percent difference (compared with placebo) p
Change in HDL cholesterol (mg/dL)
6.6
2.7
8.4
<0.001
Change in triglycerides (mg/dL)
-31.2
3.6
16.4
Scheen A. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.